Jazz Pharmaceuticals

AI Score

XX

Unlock

102.91
1.16 (1.14%)
At close: Apr 15, 2025, 3:59 PM
99.01
-3.79%
After-hours: Apr 15, 2025, 07:29 PM EDT
1.14%
Bid 98.07
Market Cap 6.25B
Revenue (ttm) 4.07B
Net Income (ttm) 560.12M
EPS (ttm) 8.65
PE Ratio (ttm) 11.9
Forward PE 4.46
Analyst Buy
Ask 104.11
Volume 939,940
Avg. Volume (20D) 1,102,896
Open 101.39
Previous Close 101.75
Day's Range 101.23 - 104.02
52-Week Range 95.49 - 148.06
Beta 0.42

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2007
Employees 2,800
Stock Exchange NASDAQ
Ticker Symbol JAZZ
Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $179, which is an increase of 73.94% from the latest price.

Stock Forecasts

Next Earnings Release

Jazz Pharmaceuticals is scheduled to release its earnings on Apr 30, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+3.22%
Jazz Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
2 months ago
+1.02%
Jazz Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $130 to $170.